KR20150125636A - A composition for the treatment and prevention of Acute gastroenteritis or Food poisoning induced by Salmonella typhimurium - Google Patents
A composition for the treatment and prevention of Acute gastroenteritis or Food poisoning induced by Salmonella typhimurium Download PDFInfo
- Publication number
- KR20150125636A KR20150125636A KR1020150148445A KR20150148445A KR20150125636A KR 20150125636 A KR20150125636 A KR 20150125636A KR 1020150148445 A KR1020150148445 A KR 1020150148445A KR 20150148445 A KR20150148445 A KR 20150148445A KR 20150125636 A KR20150125636 A KR 20150125636A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- food poisoning
- acute gastroenteritis
- salmonella typhimurium
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 206010016952 Food poisoning Diseases 0.000 title claims abstract description 32
- 208000019331 Foodborne disease Diseases 0.000 title claims abstract description 32
- 208000005577 Gastroenteritis Diseases 0.000 title claims abstract description 32
- 208000012873 acute gastroenteritis Diseases 0.000 title claims abstract description 32
- 230000002265 prevention Effects 0.000 title claims description 10
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 title abstract description 11
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims abstract description 63
- 235000011037 adipic acid Nutrition 0.000 claims abstract description 32
- 229960000250 adipic acid Drugs 0.000 claims abstract description 31
- 230000012010 growth Effects 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 230000035755 proliferation Effects 0.000 claims abstract description 10
- 241001467018 Typhis Species 0.000 claims description 15
- 208000037386 Typhoid Diseases 0.000 claims description 10
- 201000008297 typhoid fever Diseases 0.000 claims description 10
- 241000233866 Fungi Species 0.000 claims description 6
- 230000017066 negative regulation of growth Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 230000009036 growth inhibition Effects 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 230000004083 survival effect Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 239000003899 bactericide agent Substances 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- 239000003242 anti bacterial agent Substances 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 5
- 206010061393 typhus Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- -1 animals Natural products 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001502129 Mullus Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 231100000704 bioconcentration Toxicity 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 244000000021 enteric pathogen Species 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A23L1/30—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
본 발명은 헥산디올산(Hexanedioic acid)을 유효성분으로 포함하는 쥐티푸스균(Salmonella typhimurium)으로 유발되는 식중독 또는 급성위장염의 치료 또는 예방용 약학적 조성물, 예방 또는 개선용 건강식품 조성물, 예방 또는 개선용 사료 조성물에 관한 것이다.
The present invention relates to a pharmaceutical composition for the treatment or prevention of food poisoning or acute gastroenteritis caused by Salmonella typhimurium containing hexanedioic acid as an active ingredient, a health food composition for prevention or improvement, prevention or improvement Feed composition.
수백 년 전만 해도 태어난 아이의 10명 중 3명은 1살이 되기 전에 사망하였으며 절반 정도가 10살 이전에 사망하였다. 그 이유는 천연두, 홍역, 말라리아, 콜레라, 장티푸스, 결핵, 폐렴, 페스트, 패혈증과 같은 질병 때문이었다. 이러한 질병의 억제와 치료를 위한 연구 중 페니실린의 발견은 항생물질에 의한 병원균의 억제, 건강보건 향상 및 질병억제에 의한 수명연장에 큰 변화를 유발시키는 전환점이 되었다. Hundreds of years ago, 3 out of 10 children died before they were 1, and about half died before 10 years old. The reason was due to diseases such as smallpox, measles, malaria, cholera, typhoid, tuberculosis, pneumonia, plague and sepsis. Findings of penicillin during the inhibition and treatment of these diseases have become a turning point that has led to major changes in antibiotic-induced inhibition of pathogens, improvement of health health and prolongation of life by inhibition of disease.
그렇지만, 아직도 병원성 미생물과 내성균에 의한 직접 혹은 간접적인 피해는 경제, 환경, 의학 및 보건학적으로 많은 문제와 질병을 유발시키고 있다. 식품 산업에서의 식품 유통 과정 중 부패로 인한 손실, 농업에서의 농작물에 대한 과량의 화학 살충제의 사용과 수산업 양식 산업에서의 항생제 사용으로 인한 인체의 유해성 및 환경오염, 광범위한 항생제의 오남용으로 인한 항생제 내성 균주의 출현 등 사회 전반에서 많은 문제가 유발되고 있다. 특히, 최근 항생제에 광범위한 내성을 보이는 미생물들이 발견되고 항생제에 대한 내성 문제가 심각해지면서, 새로운 항생물질의 연구개발과 보급이 시급히 요구되고 있다. 또한, 일반적으로 항생제는 인간뿐만 아니라 축산업에 있어서도 매우 중요한 역할을 한다. 과거 농업을 포함하는 축, 수산업의 발전에 따라서 단위 면적당 사육두수가 증가되고 생산성을 향상시키기 위하여 질병의 예방 및 치료는 성공적인 축, 수산업의 중요한 요인으로 작용하였다. 이에 다양한 항생제와 성장촉진제들이 개발 보급되었고, 현장에서 적용되어 사용돼 왔다. 이러한 항생제 사용량의 증가는 축, 수산물에 대한 내성과 오염을 초래하였고, 더 나아가 생물농축현상을 통하여 축, 수산물을 최종 소비하고 섭취하는 인간에게 약물내성을 유발시킬 뿐만 아니라 내성 균주로 하여금 생명을 위협당하는 상황에 이르렀다.However, direct or indirect damages caused by pathogenic microorganisms and resistant bacteria still cause many problems and diseases in economy, environment, medicine and health. The use of chemical pesticides in agriculture for agricultural products and the use of antibiotics in the aquaculture industry, the harmfulness and environmental pollution of the human body, the antibiotic resistance due to abuse of a wide range of antibiotics The emergence of strains has caused many problems in society as a whole. In particular, recently, microorganisms showing extensive resistance to antibiotics have been discovered and the problem of resistance to antibiotics has become serious, and the research and development and dissemination of new antibiotics are urgently required. In addition, antibiotics generally play a very important role not only in humans but also in animal husbandry. In order to increase the number of rearing per unit area and to improve the productivity, the prevention and treatment of disease was an important factor of the successful axis and fisheries industry in accordance with the development of axis and fisheries including past agriculture. Therefore, various antibiotics and growth promoters have been developed and distributed and applied in the field. This increase in the amount of antibiotics caused resistance and contamination to axes and aquatic products. Furthermore, through the bioconcentration phenomenon, not only does it induce drug resistance to humans consuming and consuming axes and aquatic products, The situation reached.
현재 사용되고 있는 대부분의 항생제는 화학적인 합성을 통해 제조된 것으로서 상기와 같은 내성, 오염 및 부작용을 유발하는 등의 많은 한계를 나타내고 있다. 따라서 최근에는 동물, 식물, 미생물 및 다양한 한약재와 약용식물을 포함하는 천연물로부터 새로운 항균물질을 분리, 개발하고자 하는 연구가 활발하게 진행되고 있으며 항생제의 기능을 대체할 수 있는 인간 친화적 물질의 개발이 중요한 과제로 부각되고 있다. 하지만 이러한 새로운 항균물질의 연구, 개발이 쉽지만은 않은 실정이다. 새로운 항균물질을 개발하기 위해서는 항균 스펙트럼이 광범위하고 기존 내성 균주에도 항균효과를 나타내며 장기간 투여하여도 부작용없이 안전하여야 한다는 점 등을 고려해야 한다.Most of the currently used antibiotics are produced through chemical synthesis, and thus exhibit many limitations such as resistance, contamination and side effects as described above. Therefore, recently, researches for separating and developing new antimicrobial substances from natural products including animals, plants, microorganisms and various medicinal plants and medicinal plants are being actively carried out, and development of a human-friendly substance capable of replacing antibiotic functions is important It is becoming a challenge. However, research and development of these new antimicrobial substances is not easy. In order to develop a new antimicrobial substance, it is necessary to consider that the antimicrobial spectrum is broad and antimicrobial effect is exerted on existing resistant strains, and that even long-term administration is safe without side effects.
이러한 배경 하에서, 본 발명자는 새로운 항균물질을 개발하기 위하여 예의 노력하던 중, 화학물질로 알려진 “Hexanedioic acid”가 식중독 또는 급성위장염을 유발하는 쥐티푸스균에서 높은 항균활성 또는 생육저해작용을 가짐을 확인함으로써 본 발명을 완성하게 되었다.
Under such background, the present inventors have made efforts to develop a new antimicrobial substance, and found that "Hexanedioic acid", known as a chemical substance, has a high antimicrobial activity or growth inhibitory action in a mouse typhus causing food poisoning or acute gastroenteritis Thereby completing the present invention.
본 발명의 하나의 목적은 헥산디올산(Hexanedioic acid)을 유효성분으로 포함하는 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 치료 또는 예방용 약학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for the treatment or prevention of food poisoning or acute gastroenteritis caused by a mite typhi bacteria containing hexanedioic acid as an active ingredient.
본 발명의 다른 하나의 목적은 헥산디올산(Hexanedioic acid)을 유효성분으로 포함하는 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 예방 또는 개선용 건강식품 조성물을 제공하는 것이다.It is another object of the present invention to provide a health food composition for preventing or ameliorating food poisoning or acute gastroenteritis caused by a mite typhi bacteria containing hexanedioic acid as an active ingredient.
본 발명의 또 다른 하나의 목적은 헥산디올산(Hexanedioic acid)을 유효성분으로 포함하는 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 예방 또는 개선용 사료 조성물을 제공하는 것이다.
It is still another object of the present invention to provide a feed composition for preventing or ameliorating food poisoning or acute gastroenteritis caused by a typhoid fungus containing hexanedioic acid as an active ingredient.
상기 목적을 달성하기 위한 하나의 양태로서, 본 발명은 헥산디올산(Hexanedioic acid)을 유효성분으로 포함하는 쥐티푸스균(Salmonella typhimurium)으로 유발되는 식중독 또는 급성위장염의 치료 또는 예방용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for treating or preventing food poisoning or acute gastroenteritis caused by Salmonella typhimurium containing hexanedioic acid as an active ingredient, to provide.
본 발명에서 사용되는 용어 “Hexanedioic acid”는 “Adipic acid” 또는 “hexane-1,6-dioic acid” 라고도 불리며 백색 결정(White crystals)으로 화학구조식은 C6H10O4이고 몰 질량(Molar mass)은 146.14g/mole 이다. 본 발명에서는 Hexanedioic acid를 증류수로 녹여 농도별로 용액을 제조한 후 항균활성을 측정하였다. 본 발명의 일실시 예에서는 상기 Hexanedioic acid가 식중독 또는 급성위장염을 유발하는 쥐티푸스균의 성장 및 분열증식을 억제하고, 쥐티푸스균의 생존을 저해함으로써 쥐티푸스균에 대한 항균활성 또는 생육저해작용이 있음을 확인하였다(도 1 내지 2). The term "hexanedioic acid" used in the present invention is also called "adipic acid" or "hexane-1,6-dioic acid" and is white crystals having the chemical structure C 6 H 10 O 4 and the molar mass ) Is 146.14 g / mole. The antimicrobial activity of Hexanedioic acid was measured by dissolving Hexanedioic acid in distilled water. In one embodiment of the present invention, the Hexanedioic acid suppresses the growth and proliferation of rats typhi that cause food poisoning or acute gastroenteritis, and inhibits the survival of rats typhi, thereby inhibiting the antimicrobial activity or growth inhibition (Figs. 1 to 2).
본 발명에서 사용되는 용어 “쥐티푸스균(Salmonella typhimurium)”은 그람음성의 간균으로 편모가 있으며 포자는 만들지 않고 장내세균에 속하는 장관계전염병의 병원균이다. 또한, 쥐티푸스균은 대량의 균에 감염되면 동물과 사람에게 병원성을 나타내며 식중독의 원인균으로 살모넬라의 B군에 속하며 발열, 구토, 설사 등의 급성위장염을 일으킨다. As used herein, the term " Salmonella typhimurium " is a Gram-negative bacillus and is a pathogenic organism of enteric pathogens belonging to intestinal bacteria without flagella. In addition, when a large amount of bacteria is infected, it shows pathogenicity to animals and humans. As a cause of food poisoning, it belongs to group B of Salmonella and causes acute gastroenteritis such as fever, vomiting and diarrhea.
본 발명에서 상기 약학적 조성물의 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 치료 또는 예방 효과는 식중독 또는 급성위장염을 유발하는 쥐티푸스균의 성장 및 분열증식을 억제하고 생육저해작용을 유발함으로써, 쥐티푸스균에 대한 항균활성을 가짐으로써 달성되는 것일 수 있다. 본 발명의 일실시 예에서는 Hexanedioic acid가 상기 식중독 또는 급성위장염을 유발하는 쥐티푸스균에 대한 항균활성을 가짐을 확인함으로써 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 치료 또는 예방 효과를 달성할 수 있음을 확인하였다(도 1 내지 2). In the present invention, the therapeutic or prophylactic effect of food poisoning or acute gastroenteritis caused by the tumefaciens of the pharmaceutical composition in the present invention inhibits the growth and proliferation of mite typhi causing food poisoning or acute gastroenteritis and induces growth inhibition action, May be accomplished by having an antimicrobial activity against typhoid bacteria. In one embodiment of the present invention, Hexanedioic acid has antimicrobial activity against the typhus bacteria causing the food poisoning or acute gastroenteritis, thereby achieving the treatment or prevention effect of food poisoning or acute gastroenteritis caused by typhus bacteria (Figs. 1 to 2).
본 발명에서 사용되는“항균”이란 세균에 저항하는 효능, 보다 상세하게는 약제나 생리활성물질 또는 알려진 화학물질에 의한 세균 및 진균의 성장억제, 분열증식 억제 또는 생육저해작용을 의미하는 것으로서, 본 발명의 목적상 상기 식중독 또는 급성위장염을 유발하는 쥐티푸스균의 성장 및 분열증식 억제 또는 생육저해작용을 의미한다. 본 발명의 일실시 예에서는 TB assay를 통하여 상기 Hexanedioic acid가 식중독 또는 급성위장염균을 유발하는 쥐티푸스균에 대한 생육억제작용 또는 항균활성을 가짐을 확인하였다(도 1 내지 2). As used herein, the term " antibacterial " as used herein means an effect against bacteria, more specifically, a bacterial and fungal growth inhibition, proliferative growth inhibition or growth inhibitory action by a drug, a physiologically active substance or a known chemical substance. For the purpose of the present invention, the term " growth inhibition or proliferation inhibition " or growth inhibition effect of the typhus bacteria causing the food poisoning or acute gastroenteritis is implied. In one embodiment of the present invention, it was confirmed through the TB assay that the hexanedioic acid has a growth inhibitory activity or antimicrobial activity against the typhoid bacteria causing food poisoning or acute gastroenteritis (Figs. 1 and 2).
본 발명의 Hexanedioic acid는 이에 제한되지는 않으나, 화학적 합성에 의해 얻어지는 합성물질이나 동물, 식물 및 곤충에서 유래되는 물질일 수 있다. 상기 Hexanedioic acid는 당업계에 공지된 일반적인 합성방법, 동물, 식물 및 곤충에서 유래되는 추출방법이나 분리 및 정제방법을 이용하여 얻어질 수 있다. 또한, 상기 추출물의 추출방법은 이에 제한되지는 않으나, 바람직하게는 유기용매추출, 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출 또는 초음파 추출 등의 방법을 사용할 수 있다. The hexanedioic acid of the present invention is not limited thereto, but may be a synthetic material obtained by chemical synthesis or a substance derived from an animal, a plant and an insect. The hexanedioic acid can be obtained by an extraction method or a separation and purification method derived from common synthetic methods, animals, plants and insects known in the art. The extraction method of the extract is not limited thereto, but organic solvent extraction, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction may be used.
본 발명에서 상기 Hexanedioic acid를 분리, 정제하거나 제조하기 위한 추출물의 추출에 사용되는 용매는 당업계에서 통상적으로 사용하는 물이나 유기용매를 사용할 수 있으며, 이에 제한되지는 않으나 물, 헥산, 클로로포름, 탄소수 1 내지 6의 알코올 또는 이들의 혼합 용매를 사용할 수 있으며, 보다 바람직하게는 헥산, 클로로포름, 에탄올, 메탄올, 부탄올, 아세테이트, 아세톤, 아세토니트릴, 벤젠, 디클로로메탄 또는 이들의 혼합 용매를 사용할 수 있다. In the present invention, the solvent used for extracting, extracting, or preparing the hexanedioic acid may be water or organic solvent commonly used in the art. Examples of the solvent include water, hexane, chloroform, Ethanol, methanol, butanol, acetate, acetone, acetonitrile, benzene, dichloromethane, or a mixed solvent thereof may be used as the solvent.
본 발명에서 사용되는 “예방”은 상기 조성물의 투여로 상기 질환의 발병을 억제 또는 지연시키는 모든 행위를 의미하며 “치료”는 상기 조성물의 투여로 상기 질환의 증세가 호전되거나 이롭게 되는 모든 행위를 의미한다.&Quot; Prevention " used in the present invention means all the actions of inhibiting or delaying the onset of the disease upon administration of the composition, and " treatment " means any action that alleviates or alleviates symptoms of the disease upon administration of the composition do.
본 발명의 약학적 조성물은 약제학적으로 허용 가능한 담체를 포함할 수 있다. 약학적으로 허용 가능한 담체를 포함하는 조성물은 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제환제, 산제, 과립제, 캡슐제 등이 포함될 수 있으며 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함될 수 있다. 비수성용제, 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테로 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier. Compositions comprising a pharmaceutically acceptable carrier can be of various oral or parenteral formulations. In the case of formulation, it can be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used. Solid formulations for oral administration may include tablet pills, powders, granules, capsules, and the like, which may contain one or more excipients, such as starch, calcium carbonate, sucrose, or lactose lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
또한, 본 발명의 약학적 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제 및 좌제로 이루어진 군으로부터 선택되는 어느 하나의 제형을 가질 수 있다. The pharmaceutical composition of the present invention may also be in the form of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, Or a pharmaceutically acceptable salt thereof.
본 발명의 약학적 조성물은 그 투여용량에 특별한 제약은 없고, 체내 흡수도, 체중, 환자의 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율 및 질환의 중증도 등에 따라 변화될 수 있다. 본 발명의 약학적 조성물은 유효량 범위를 고려하여 제조하도록 하며, 이렇게 제형화된 단위 투여형 제제는 필요에 따라 약제의 투여를 감시하거나 관찰하는 전문가의 판단과 개인의 요구에 따라 전문화된 투약법을 사용하거나 일정 시간 간격으로 수회 투여할 수 있다.
The dosage form of the pharmaceutical composition of the present invention is not particularly limited and may be varied depending on the degree of absorption, body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, have. The pharmaceutical composition of the present invention is prepared in consideration of an effective dose range, and the unit dosage formulations thus formulated are classified according to the judgment of the expert who monitors or observes the administration of the drug, if necessary, Or may be administered several times at a predetermined time interval.
다른 하나의 양태로서, 본 발명은 헥산디올산(Hexanedioic acid)을 유효성분으로 포함하는 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 예방 또는 개선용 건강식품 조성물을 제공한다. 상기 건강식품 조성물은 바람직하게는 식중독 또는 급성위장염을 유발하는 쥐티푸스균의 성장 및 분열증식을 억제하고 생육저해작용을 유발함으로써, 쥐티푸스균에 대한 항균활성을 가짐으로써 달성되는 것일 수 있으며, 이에 대해서는 상기에서 설명한 바와 같다. In another aspect, the present invention provides a health food composition for preventing or ameliorating food poisoning or acute gastroenteritis caused by the typhimurium including hexane diol acid (Hexanedioic acid) as an active ingredient. The health food composition may preferably be achieved by inhibiting the growth and proliferation of rats typhi causing food poisoning or acute gastroenteritis and inducing a growth inhibitory action to have an antimicrobial activity against rats typhi. As described above.
본 발명의 조성물을 건강식품의 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 건강식품 또는 그 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용목적에 따라 적합하게 결정될 수 있으며, 본 발명의 조성물은 혼합량에 큰 제한은 없다. When the composition of the present invention is used as an additive for a health food, the composition may be added as it is or may be used together with other health food or its components, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed may be appropriately determined depending on the purpose of use, and the amount of the composition of the present invention is not particularly limited.
본 발명의 건강식품의 종류에는 기능성식품, 식품첨가물, 영양보조제 등의 형태를 포함하며 특별한 제한은 없다. 상기 조성물을 첨가할 수 있는 건강식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있고 통상적인 의미에서의 건강식품을 모두 포함할 수 있으며, 동물을 위한 사료로 이용되는 식품을 포함할 수 있다. 또한, 본 발명의 건강기능식품 조성물이 음료의 형태로 사용될 경우에는 통상의 음료와 같이 여러 가지 감미제, 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.
The types of health foods of the present invention include functional foods, food additives, nutritional supplements, and the like, and there is no particular limitation. Examples of the health food to which the composition can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, soups, drinks, tea, , Alcoholic beverages, and vitamin complexes, and may include foods used as feed for animals, which may include all health foods in a conventional sense. In addition, when the health functional food composition of the present invention is used in the form of a drink, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as additional components such as ordinary beverages. In addition to the above, the health functional food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, , Alcohols, carbonating agents used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
또 다른 하나의 양태로서, 본 발명은 헥산디올산(Hexanedioic acid)을 유효성분으로 포함하는 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 예방 또는 개선용 사료 조성물을 제공한다. 상기 사료 조성물은 바람직하게는 식중독 또는 급성위장염을 유발하는 쥐티푸스균의 성장 및 분열증식을 억제하고 생육저해작용을 유발함으로써, 쥐티푸스균에 대한 항균활성을 가짐으로써 달성되는 것일 수 있으며, 이에 대해서는 상기에서 설명한 바와 같다. In another aspect, the present invention provides a feed composition for preventing or ameliorating food poisoning or acute gastroenteritis caused by a mite typhi bacteria containing hexanedioic acid as an active ingredient. The feed composition may preferably be achieved by inhibiting the growth and proliferation of rats typhi causing food poisoning or acute gastroenteritis and causing an inhibitory effect on growth, thereby having an antimicrobial activity against the mouse typhi bacteria, As described above.
본 발명의 조성물을 사료 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 사료 성분과 함께 혼합하여 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용목적에 따라 적합하게 결정될 수 있으며 본 발명의 조성물은 혼합량에 큰 제한은 없다. When the composition of the present invention is used as a feed additive, the composition may be added as it is or may be mixed with other feed ingredients and used appropriately according to a conventional method. The amount of the active ingredient to be mixed may be appropriately determined depending on the purpose of use, and the amount of the composition of the present invention is not particularly limited.
본 발명의 사료의 종류에는 특별한 제한은 없다. 상기 조성물은 보조 성분으로 아미노산, 무기염류, 비타민, 항산화, 미생물 제제 등과 같은 각종 보조제 및 분쇄 또는 파쇄된 밀, 보리, 옥수수 등의 식물성 단백질사료, 혈분, 육분, 생선분 등의 동물성 단백질 사료, 동물성 지방 및 식물성 지방과 같은 주성분 이외에도 영양 보충제, 성장 촉진제, 소화 흡수 촉진제, 질병 예방제와 함께 사용될 수 있다. 상기 사료의 투여 형태, 방법 및 제형은 다양할 수 있으며, 이는 상기에서 설명한 바와 같다.There is no particular limitation on the kind of feed of the present invention. The composition may be supplemented with various kinds of auxiliaries such as amino acids, inorganic salts, vitamins, antioxidants, microbial preparations and the like and crushed or crushed wheat, vegetable protein feeds such as barley and corn, animal protein feeds such as blood, May be used in combination with nutritional supplements, growth promoters, digestion-absorption promoters, and disease prevention agents in addition to the main components such as fat and vegetable fats. The dosage form, method and formulation of the feed can vary and are as described above.
본 발명의 사료 조성물은 포유류, 가금류, 어류 및 갑각류를 포함하는 다수의 동물 식이 즉, 사료에 적용할 수 있다. 상업용으로 중요한 소, 돼지, 말, 사슴, 염소 등의 가축을 포함하는 포유류, 코끼리, 낙타, 기린, 원숭이 등의 동물원 동물, 개, 고양이 등의 애완동물에게 사용할 수 있으며, 닭, 오리, 거위, 비둘기 등의 가금류 및 붕어, 잉어, 송어, 숭어, 새우와 같은 상업적으로 사육되는 어류 및 갑각류에 사용할 수 있으나, 이에 제한되지는 않는다.
The feed composition of the present invention can be applied to a large number of animal diets, i.e. feeds, including mammals, poultry, fish and crustaceans. It can be used for zoo animals such as elephants, camels, giraffes and monkeys, pets such as dogs and cats, including chickens, ducks, geese, Pigeons, and other commercially available fish and crustaceans such as carp, carp, trout, mullet, and shrimp.
본 발명에 따른 약학적 조성물, 건강식품 조성물 및 사료 조성물은 식중독 또는 급성위장염을 유발하는 쥐티푸스균의 성장 및 분열증식을 억제하고 생육저해작용을 유발함으로써, 쥐티푸스균에 대한 항균활성을 가짐으로써 쥐티푸스균으로 유발되는 식중독 또는 급성위장염의 치료, 개선 또는 예방용으로 사용될 수 있는 항균제를 제공할 수 있다.
The pharmaceutical compositions, health food compositions and feed compositions according to the present invention inhibit the growth and proliferation of rats typhi causing food poisoning or acute gastroenteritis and induce growth inhibition action, thereby having antimicrobial activity against rats typhi It is possible to provide an antibacterial agent which can be used for the treatment, improvement or prevention of food poisoning or acute gastroenteritis caused by typhus.
도 1은 Hexanedioic acid를 TB assay에 적용하여 식중독 또는 급성위장염을 유발하는 쥐티푸스균의 성장 및 분열증식 억제 또는 생존저해작용에 대한 Hexanedioic acid의 농도별 항균활성을 도표로 나타낸 것이다. 또한 "+" 는 쥐티푸스균에 대한 상기 시험물질의 생육저해작용 또는 항균활성 또는 항균효과를 나타낸다.
도 2는 Hexanedioic acid를 TB assay에 적용하여 식중독 또는 급성위장염을 유발하는 쥐티푸스균의 성장 및 분열증식 억제 또는 생존저해작용에 대한 Hexanedioic acid의 농도별 항균활성 결과를 그래프로 나타낸 것이다. FIG. 1 is a graph showing the antimicrobial activity of hexapyridium acid against the growth and mitogenic inhibition or survival inhibition of typhoid fungus, which induces food poisoning or acute gastroenteritis by applying hexanedioic acid to TB assay. In addition, "+" indicates the growth inhibitory action, antimicrobial activity or antimicrobial effect of the above-mentioned test substance against S. typhimurium.
FIG. 2 is a graph showing the results of antimicrobial activity of Hexanedioic acid according to the concentration of Hexanedioic acid applied to the TB assay to inhibit the growth and proliferation inhibition or survival inhibition of the typhoid fungus causing food poisoning or acute gastroenteritis.
이하, 본 발명을 실시 예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
실시예Example 1: One: TBTB assayassay 에 의한 시험물질의 항균활성 측정 Measurement of antimicrobial activity of test substance by
식중독 또는 급성위장염을 유발하는 쥐티푸스균에 대한 Hexanedioic acid의 항균활성 또는 항균효과를 측정하기 위하여 Hexanedioic acid와 증류수를 사용하여 Hexanedioic acid 용액을 농도별로 제조한 후 TB assay에 적용하여 쥐티푸스균에 대한 상기 시험물질의 항균활성을 측정하였다. To determine antimicrobial activity or antimicrobial effect of Hexanedioic acid against mite typhi which cause food poisoning or acute gastroenteritis, Hexanedioic acid and distilled water were used to prepare Hexanedioic acid solution by concentration and then applied to TB assay. The antimicrobial activity of the test substance was measured.
TB assay의 과정은 다음과 같다. 먼저 유리 플라스크나 병에 LB(Luria-Bertani broth) 액체 배지를 담은 후 LB(Luria-Bertani broth) 액체 배지에 상기 시험균주를 접종하고 37℃ 배양기에서 24시간 동안 배양하였다. 이후, 시험균주를 96-웰 플레이트(96-well plate)의 각 웰에 150㎕씩 첨가하고 상기 시험 용액을 농도별로 투여한 후, 12시간 후에 각 균주의 흡광도를 측정하고 시험 용액을 투여하지 않은 정상 배양 균주의 흡광도와 비교 측정하여 항균활성 %를 계산하였다. The TB assay procedure is as follows. First, the LB (Luria-Bertani broth) liquid medium was placed in a glass flask or bottle, and then the test strain was inoculated in a LB (Luria-Bertani broth) liquid medium and cultured in a 37 ° C incubator for 24 hours. Thereafter, 150 μl of the test strain was added to each well of a 96-well plate, and the test solution was administered at the concentration. After 12 hours, the absorbance of each strain was measured and the test solution was not administered The percent antimicrobial activity was calculated by comparing the absorbance of the normal culture with the absorbance.
그 결과, TB assay 실험을 통하여, 상기 시험물질인 Hexanedioic acid는 쥐티푸스균에 농도-의존적으로 높은 생육저해작용 또는 항균활성을 가지고 있음이 확인되었다(도 1 내지 2). 이러한 결과는 Hexanedioic acid가 쥐티푸스균으로 유발되는 식중독 또는 급성위장염균에 대한 항균용 조성물로서 이용 가능함을 의미한다.As a result, it was confirmed through the TB assay experiment that the test substance Hexanedioic acid had a high concentration inhibition activity or antimicrobial activity in the mouse typhi bacteria (FIGS. 1 and 2). These results indicate that hexanedioic acid can be used as an antimicrobial composition against food poisoning or acute gastroenteritis caused by typhoid bacteria.
Claims (4)
A pharmaceutical composition for the treatment or prevention of food poisoning or acute gastroenteritis caused by a typhoid fungus containing hexanedioic acid as an active ingredient.
The pharmaceutical composition according to claim 1, wherein the composition induces growth and proliferation or inhibition of growth of the mite typhi causing food poisoning or acute gastroenteritis.
A health food composition for preventing or ameliorating food poisoning or acute gastroenteritis caused by a typhoid fungus containing hexanedioic acid as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150148445A KR20150125636A (en) | 2015-10-26 | 2015-10-26 | A composition for the treatment and prevention of Acute gastroenteritis or Food poisoning induced by Salmonella typhimurium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150148445A KR20150125636A (en) | 2015-10-26 | 2015-10-26 | A composition for the treatment and prevention of Acute gastroenteritis or Food poisoning induced by Salmonella typhimurium |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120072044A Division KR101580008B1 (en) | 2012-07-03 | 2012-07-03 | A composition for the treatment or prevention of pneumonia comprising Hexanedioic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150125636A true KR20150125636A (en) | 2015-11-09 |
Family
ID=54605058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150148445A KR20150125636A (en) | 2015-10-26 | 2015-10-26 | A composition for the treatment and prevention of Acute gastroenteritis or Food poisoning induced by Salmonella typhimurium |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20150125636A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102049522B1 (en) * | 2018-06-05 | 2019-11-27 | 충남대학교산학협력단 | Composition for Prohylaxis and Treatment of Infectious Disease by Salmonella Comprising GABA |
-
2015
- 2015-10-26 KR KR1020150148445A patent/KR20150125636A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102049522B1 (en) * | 2018-06-05 | 2019-11-27 | 충남대학교산학협력단 | Composition for Prohylaxis and Treatment of Infectious Disease by Salmonella Comprising GABA |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101428157B1 (en) | Antibacterial composition comprising Hermetia illucens larval extracts or fractions thereof | |
| KR101467698B1 (en) | Anti-microbial composition comprising cynanchi wilfordii radix extract and the use thereof | |
| KR101795115B1 (en) | Anti-tuberculosis composition for treating or preventing tuberculosis comprising gamma-Linolenic acid | |
| KR101623318B1 (en) | A composition comprising Hexanedioic acid for the treatment or prevention of shigellosis | |
| KR102218992B1 (en) | Composition for preventing, ameliorating or treating autism spectrum disorder comprising Agathobaculum sp. strain as effective component | |
| KR20150125636A (en) | A composition for the treatment and prevention of Acute gastroenteritis or Food poisoning induced by Salmonella typhimurium | |
| KR101775223B1 (en) | A composition for treating or preventing tuberculosis comprising Artesunate | |
| JP2019170335A (en) | Intestinal short-chain fatty acid production promoting composition | |
| KR101623317B1 (en) | A composition comprising Hexanedioic acid for treating or preventing typhoid fever | |
| KR102159019B1 (en) | Composition for preventing or treating obesity comprising Honeybee Drone Pupas | |
| KR101623319B1 (en) | A composition inculding Hexanedioic acid for treatment or prevention of disease induced by methicillin-resistant Staphylococcus aureus | |
| KR102069622B1 (en) | Pharmaceutical composition for prevention or treatment of cancer comprising Lactobacillus fermentum WiKim0102 as active ingredient | |
| KR101623316B1 (en) | A composition for the treatment or prevention of diphtheriae comprising Hexanedioic acid | |
| KR101580008B1 (en) | A composition for the treatment or prevention of pneumonia comprising Hexanedioic acid | |
| KR20200058353A (en) | Antimicrobial composition comprising the hexane and butanol fractions of teleogryllus emma extract | |
| KR101798286B1 (en) | A composition for treating or preventing tuberculosis comprising Linolenic acid | |
| KR20150123772A (en) | A composition for the treatment and prevention of gonorrhea or disease induced by Neisseria gonorrhoeae comprising Hexanedioic acid | |
| US20240091281A1 (en) | Pharmaceutical composition for preventing or treating intestinal damage comprising leuconostoc citreum strain as active ingredient | |
| KR102546973B1 (en) | Composition for enhancing immunity comprising Bacillus velenzensis Kh2-2 | |
| KR102244732B1 (en) | Probiotic acetic acid bacteria Acetobacter pasteurianus MGLV and its immunomodulatory effect | |
| JP7206623B2 (en) | Composition for prevention and improvement of glucose metabolism disorder | |
| KR101810292B1 (en) | A composition for treating or preventing tuberculosis comprising Conjugated(10E,12Z)-Linoleic acid | |
| KR101810290B1 (en) | A composition for treating or preventing tuberculosis comprising Conjugated(9Z,11E)-Linoleic acid | |
| KR20170111997A (en) | A protein composition for the treatment and prevention of disease induced by Neisseria gonorrhoeae or Gonorrhea comprising protein or protein fractions derived from Hermetia illucens larvae | |
| KR101810291B1 (en) | A composition for treating or preventing tuberculosis comprising Conjugated(9E,11E)-Linoleic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| WITN | Withdrawal due to no request for examination |